半胱氨酸蛋白酶抑制SN在肝细胞癌中的表达意义

肝癌电子杂志 ›› 2021, Vol. 8 ›› Issue (2): 33-38.

半胱氨酸蛋白酶抑制SN在肝细胞癌中的表达意义

吴杰, 高飞, 张雪松, 王魁阳, 隋成旭, 张亮, 姚远方, 宋磊^*

大连医科大学附属第二医院综合介入科,辽宁大连 116027

收稿日期:2020-10-16 发布日期:2021-07-16
通讯作者: *宋磊,E-mail: songlei_1975@126.com
作者简介:吴杰, 主治医师,大连医科大学附属第二医院,综合介入科
基金资助:
大连市医学科学研究计划项目（1712033）

The significance of cystatin SN expression in hepatocellular carcinoma

Wu Jie, Gao Fei, Zhang Xuesong, Wang Kuiyang, Sui Chengxu, Zhang Liang, Yao Yuanfang, Song Lei^*

Department of Interventional Therapy, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China

Received:2020-10-16 Published:2021-07-16

摘要/Abstract

摘要： 目的: 分析肝细胞癌（hepatocellular carcinoma,HCC）中半胱氨酸蛋白酶抑制SN的表达水平及其与各临床病理特征之间的关系,探讨半胱氨酸蛋白酶抑制SN表达水平与HCC患者预后之间的联系。方法: 收集72例原发性肝癌患者的临床信息,采用免疫组织化学法检测72份HCC组织及60份癌旁组织蜡块标本中半胱氨酸蛋白酶抑制SN的表达,分析半胱氨酸蛋白酶抑制SN在72份HCC组织与60份癌旁组织中的表达情况,及其相关临床意义。结果: 半胱氨酸蛋白酶抑制SN在60份癌旁组织中均呈现强阳性表达（+++）,其表达强度均明显强于HCC组织,两组表达程度有显著性差异（P<0.05）。HCC组织中半胱氨酸蛋白酶抑制SN表达水平高的患者生存预后均优于其表达水平低的患者（均P<0.05）。结论: HCC组织半胱氨酸蛋白酶抑制SN的表达相比癌旁组织明显较低,且半胱氨酸蛋白酶抑制SN高表达的HCC患者生存预后均要明显优于其低表达的患者。

关键词: 肝细胞癌, 半胱氨酸蛋白酶抑制 SN, 无瘤生存, 总生存

Abstract: Objective: To analyze the expression level of cystatin Sn in HCC and its relationship with clinicopathological features, and to explore the relationship between the expression level of cystatin SN and the prognosis of HCC patients. Methods: The clinical data of 72 patients with primary liver cancer were collected, and the expression of cystatin SN was detected by immunohistochemistry in 72 HCC and 60 paraffin samples of paracancerous tissues. Results: The expression intensity of cystatin SN was significantly higher than that of HCC (P<0.05). The patients with high expression level of cystatin SN in HCC were better than those with low expression level in disease-free survival and overall survival (P<0.05). Conclusion: The expression of cystatin SN in HCC is significantly lower than that in paracancerous tissues, and the HCC patients with high expression of cystatin SN were significantly better than those with low expression in disease-free survival and overall survival.

Key words: Hepatocellular carcinoma, Cystatin SN, Disease-free survival, Overall survival

吴杰, 高飞, 张雪松, 王魁阳, 隋成旭, 张亮, 姚远方, 宋磊. 半胱氨酸蛋白酶抑制SN在肝细胞癌中的表达意义[J]. 肝癌电子杂志, 2021, 8(2): 33-38.

Wu Jie, Gao Fei, Zhang Xuesong, Wang Kuiyang, Sui Chengxu, Zhang Liang, Yao Yuanfang, Song Lei. The significance of cystatin SN expression in hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(2): 33-38.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] 应倩,汪媛.肝癌流行现况和趋势分析[J/OL].中国肿瘤,2020,29(3):185-191.
[3] OH BYUNGMOO, LEE SEON-JIN, CHO HEE JUN, et al.cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer[J]. Cell Death Dis, 2017, 8(9): e3053.
[4] CHOIEH, KIMJT, KIMJH, et al. Upregulation of the cysteine protease inhibitor, cystatinSN, contributes to cell proliferation and cathepsin inhibition in gastric cancer[J]. Clin Chim Acta, 2009, 406(1-2): 45-51.
[5] YOU-FANG CHEN, GANG MA, XUN CAO, et al.Overexpression of cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma[J]. BMC Surg, 2013, 28: 13-15.
[6] 何娟,冯震博.半胱氨酸蛋白酶抑制剂与恶性肿瘤的研究进展[J].医学综述,2010,(3):374-376.
[7] JIANG J, LIU HL, TAO L, et al.Let-7d inhibits colorectal cancer cell proliferation through the CST1/p65 pathway[J]. International Journal of Oncology, 2018, 53(2): 781-790.
[8] KIM JT, LEE SJ, KANG MA, et al.cystatin SN neutralizes the inhibitory effect of cystatin C on cathepsin B activity[J]. Cell Death Dis, 2013, 19(4): e974.
[9] JIANG J, LIU HL, LIU ZH, et al.Identification of cystatin SN as a novel biomarker for pancreatic cancer[J]. Tumor Biology, 2015, 36(5): 3903-3910.
[10] KUMEM, YASUIH, YOSHIKAWAY, et al. Transient elevation of serum cystatin C concentrations during perioperative cisplatin- based chemotherapy in esophageal cancer patients[J]. Cancer Chemother Pharmacol, 2012, 69(6): 1537-1544.
[11] VASILJEVA O, KOROVIN M, GAJDA M, et al.Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice[J]. Oncogene, 2008, 27: 4191-4199.
[12] FAN QL, WANG X, ZHANG H, et al.Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro[J]. Biochem Biophys Res Commun, 2012, 425(4): 703-710.
[13] KIMJINA, BAEDONG-HYUCK, KIMJONGHWAN, et al. HOXC10 overexpression promotes cell proliferation and migration in gastric cancer[J]. Oncology reports, 2019, 42(1): 202-212.
[14] CHEN YF, MA G, CAO X, et al.Overexpression of cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma[J]. BMC Surg, 2013, 28(13): 15.
[15] DICKINSONDP, THIESSEM, HICKSMJ. Expression of type 2 cystatin genes CST1-CST5 in adult human tissues and the developing submandibulargland[J]. DNA Cell Biol, 2002, 21(1): 47-65.
[16] PARkKERBS, CIOCCADR, BIDWELLBN, et al. Primary tumour expression of the cysleine cathepsin inhibitor stefin A inhibits distant meas in breast cancer[ J]. J Pathol, 2008, 214(3): 337-346.
[17] EBERTE, WERLEB, JULLB, et al. Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue[J] . Adv Exp Med Biol, 1997, 421: 259-265.
[18] STROJANP, OBLAKI, SVETICB, et al. Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis[J]. Br J Cancer, 2004, 90(10): 1961-1968.
[19] SHRIDHAR R, ZHANG J, SONG J, et al.cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells[J]. Oncogene, 2004, 23(12): 2206-2215 .